medicaid covered glp 1 McKee's proposed FY2027 budget drops GLP-1 drugs for weight loss from • Rhode Island Current CMS Expands Access to GLP-1

Meng et al

This pattern of shifting payer price leadership across similar services highlights the fragmented and inconsistent nature of commercial contracting, with material implications for employer-sponsored healthcare spending

Patients prescribed GLP-1 receptor agonists should: Receive proper training on injection technique Be monitored regularly for efficacy and adverse effects Report any suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or the Yellow Card app) Understand that these medicines are part of a comprehensive treatment plan including diet and lifestyle modifications The synthetic manufacturing process and stringent regulatory oversight ensure that GLP-1 medicines meet the highest pharmaceutical standards, with no risk of venom-related contamination or variability

Food and Drugs Administration

If people lose weight without following a decent dieet protecting their muscle mass, they risk: A slower metabolism through muscle loss Brittle bones Lack of micronutrients Greater fatigue Rapid weight regain once medication is stopped In other words, the drug can dampen food noise but unless you build a foundation of muscle, nutrition, and habits, the weight will be back